ViewRay secures FDA clearance for MRIdian upgrades

By staff writers

February 21, 2019 -- Image-guided radiation therapy developer ViewRay has received clearance from the U.S. Food and Drug Administration (FDA) for new soft-tissue visualization capabilities for its MRIdian MRI-guided radiation therapy system.

The system's new capabilities include expanded high-definition visualization and enhanced contrast between different tissues, a diffusion-weighted imaging feature that tracks treatment progress by distinguishing between tumor and normal tissues, and faster and more detailed anatomical planar imaging, the company said.

The system also features ViewRay's SmartVision MRI, which supports high-fidelity beam delivery; its SmartAdapt software, which allows clinicians to generate daily MR setup scans quickly; and its SmartTarget tool, which images the tumor's edges and surrounding organ position in real-time, according to the firm.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking